跳至主要内容
临床试验/NCT06507852
NCT06507852已完成不适用

Retrospective Assessment of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness Among ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia Patients Prescribed LEQVIO® (Inclisiran) in a Real-world Setting

Novartis1 个研究点 分布在 1 个国家目标入组 95 人开始时间: 2022年10月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Novartis
入组人数
95
试验地点
1
主要终点
Percentage of Patients who Received Inclisiran Dose 2 and 3 Within Specified Time Intervals

研究概览

简要总结

This was a descriptive, non-interventional, retrospective cohort study among patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia, ASCVD-risk equivalent (ASCVD-RE) or familial hypercholesterolemia (FH) administered inclisiran in a real-world setting in Austria.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who were 18 years or older.
  • Signed informed consent was obtained.
  • Patients who received at least one inclisiran injection in the identification period.
  • Patients with at least one diagnosis of ASCVD, ASCVD-RE or FH diagnosis prior to index date.
  • Patients with at least one low-density lipoprotein cholesterol (LDL-C) measurement of 70 milligrams per deciliter (mg/dL) or greater, within 6 months prior to index date.
  • ASCVD was defined as previous diagnosis of coronary artery disease (CAD), peripheral artery disease (PAD) or cerebrovascular disease (CVD).
  • ASCVD-RE was defined as: no previous diagnosis of ASCVD at any time on the patient chart and they met at least one of the following criteria:
  • Diagnosis of type II diabetes mellitus (T2DM).
  • Diagnosis of type I diabetes mellitus (T1DM) of long duration (greater than 20 years).
  • 10-year risk of 20% or greater by Framingham risk score.

排除标准

  • 未提供

结局指标

主要结局

Percentage of Patients who Received Inclisiran Dose 2 and 3 Within Specified Time Intervals

时间窗: Up to 26 months

Time intervals: * Time from Dose 1 to Dose 2: 5 months or less. * Time from Dose 2 to Dose 3: * Less than 6 months. * Between 6 months and 9 months. * Greater than 9 months.

次要结局

  • Glycated hemoglobin(Baseline)
  • Prescribing Physician Specialty(Baseline)
  • Body Mass Index(Baseline)
  • Lipoprotein(a)(Baseline)
  • Creatinine(Baseline)
  • Alanine Aminotransferase(Baseline)
  • Aspartate Aminotransferase(Baseline)
  • Alkaline phosphatase(Baseline)
  • Physical Activity(Baseline)
  • Percentage of Patients who Received Inclisiran Doses Within Specified Time Intervals(Up to 26 months)
  • Age(Baseline)
  • Percentage of Atherosclerotic Cardiovascular Disease (ASCVD) Patients Categorized by Qualifying Diagnosis(Baseline)
  • Gender(Baseline)
  • Race(Baseline)
  • Smoking Status(Baseline)
  • Height(Baseline)
  • Blood Pressure(Baseline)
  • Percentage of Female Patients by Age Group(Baseline)
  • Percentage of Patients Categorized by Comorbidities(Baseline)
  • Cholesterol(Baseline)
  • Apolipoprotein B(Baseline)
  • Percentage of ASCVD-risk Equivalent Patients Categorized by Qualifying Criteria(Baseline)
  • Percentage of Patients Categorized by Lipid Lowering Therapies (LLTs) Prior to Index Date(Up to 6 months pre-index date)
  • Percentage of Patients Taking Different Concomitant Lipid Lowering Therapy (LLT) at Index Date(Day 1 of Month 6)
  • Weight(Baseline)
  • Percentage of Male Patients by Age Group(Baseline)
  • Triglycerides(Baseline)
  • Percentage of Patients With Procedures(Baseline)

研究者

发起方
Novartis
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验